Daniel Giraldo Perez
BofA Securities, Research Division

Analyst here at BofA. Our next presenting company is 4D Molecular Therapeutics. I have some members from the management team here. So welcome, guys. Thank you for joining us. Maybe we can start with a couple of introductions from your side, and then you can give us a high-level overview of the company. And I know you have some catalysts coming up, especially 2027 is going to be a big year for the company. So maybe we can start with that. So David, maybe if you want to start.

David Kirn
Co-Founder, President, CEO & Director

Yes. Thanks, Daniel, for having us. I'm Dave Kirn, Co-Founder, President and CEO.

Daniel Giraldo Perez
BofA Securities, Research Division

Chris?

Christopher Simms
Chief Commercial & Business Officer

Thanks, Daniel. Chris Simms, Chief Commercial and Business Officer.

Kristian Humer
CFO and Principal Financial & Accounting Officer

Kristian Humer, CFO.

David Kirn
Co-Founder, President, CEO & Director

So I can give the high-level overview of the company. So 4D Molecular Therapeutics is really a leader in next-generation AAV gene therapy. We're a platform and product company with a lead asset 4D-150 in Phase III for wet AMD and soon to be in Phase III for diabetic macular edema as well. We believe we really have the opportunity to be a best-in-class, highly durable backbone therapy for these neovascular diseases of the retina. So we're thrilled to be in Phase III. The enrollment has been extremely rapid, probably double